RxSight (RXST) Corporate presentation summary

Company overview and market position

• Employs approximately 500 people and has performed around 300,000 LAL procedures since inception.

• Over 1,100 ophthalmic offices equipped with LDDs and more than 2,500 surgeons trained.

• Holds about 10% of the US premium IOL market and maintains over $225 million in cash and short-term investments.

Product innovation and clinical outcomes

• Adjustable lens technology enables post-surgical customization, delivering superior refractive precision and patient satisfaction.

• LAL eyes have 14.5 times better odds of achieving optimal visual outcomes compared to other lenses.

• Over 94% of patients achieve high refractive accuracy, and more than 90% reach 20/25 distance and J2 near vision without glasses.

• 90% of surveyed customers believe LAL provides the highest quality of vision; 79% would choose it for their own surgery.

Financial performance and growth

• Total revenue grew from $14.7 million in 2020 to a preliminary $139.9 million in 2024.

• LAL units sold and LDD installed base have shown consistent year-over-year growth.

• Average additional net revenue per LAL implanted is $2,064, with 40% of LAL patients converting from standard lenses.